Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.26 USD | +1.57% | +1.23% | +2.29% |
Evolution of the average Target Price on Intra-Cellular Therapies, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Intra-Cellular Therapies, Inc.
Canaccord Genuity | |
Needham & Co. | |
Mizuho Securities | |
Goldman Sachs | |
Baird | |
BofA Securities | |
TD Cowen | |
Morgan Stanley | |
RBC Capital Markets | |
UBS | |
JPMorgan Chase | |
Piper Sandler | |
SVB Leerink | |
Jefferies & Co. |
EPS Revisions
- Stock Market
- Equities
- ITCI Stock
- Consensus Intra-Cellular Therapies, Inc.